.svg)
Getting back to a healthy weight after having a baby is one of many things on a new mom’s mind. With many people taking tirzepatide for weight management—the active ingredient in GLP-1 medications like Zepbound® and Mounjaro®, both manufactured by Eli Lilly—it’s no surprise that postpartum women are asking: is tirzepatide safe to use while breastfeeding?
Here’s what we know from the latest research and clinical guidance.
What is tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it mimics two naturally occurring gut hormones (GIP and GLP-1) that regulate appetite, blood sugar, and digestion. Originally developed to treat type 2 diabetes under the brand name Mounjaro, tirzepatide received FDA approval for chronic weight management as Zepbound in 2023. In clinical trials, it has produced some of the most significant weight-loss results of any GLP-1 medication currently available.*
Compounded tirzepatide injections have also become widely available through telehealth platforms, making the medication more accessible for more people.
Why postpartum women are asking about tirzepatide
The postpartum period is one of the most physically demanding stretches of a woman’s life. Hormonal shifts, sleep deprivation, the caloric demands of breastfeeding, and the stress of caring for a newborn all collide at once.
On top of that is the desire to lose the baby weight, which, for many women, doesn’t simply come off on its own. Research shows that up to 20% of women retain 9 or more pounds gained during pregnancy, and lifestyle changes that seem simple in theory—more exercise, fewer calories—can feel impossible when you’re running on four hours of sleep and feeding a baby around the clock.
Can you take tirzepatide while breastfeeding?
The current answer is no. Tirzepatide—whether as Zepbound, Mounjaro, or a compounded version—is not approved for use during the breastfeeding period. Current clinical guidance recommends avoiding it while nursing.
This isn’t unique to tirzepatide. The same recommendation applies across all GLP-1 and dual GIP/GLP-1 medications. The core issue is lack of sufficient human safety data. Without robust research confirming that tirzepatide poses no risk to a nursing infant, most providers will advise waiting until breastfeeding has completely stopped before starting or restarting tirzepatide treatment.
If you’re managing a condition like type 2 diabetes and currently take tirzepatide, speak with your provider before making any changes.
Does tirzepatide pass into breast milk?
This is one of the most common questions nursing moms ask. In a single-dose clinical lactation study from 2024, 11 healthy lactating women were given a 5 mg dose of tirzepatide. Tirzepatide was undetectable in 164 of 171 milk samples, with the remaining 7 samples showing cumulative transfer of less than 0.02% of the maternal dose. While this is encouraging, it is a very small sample size that warrants more study before we can fully understand the effects of tirzepatide, if any, on breast milk.
From a theoretical standpoint, tirzepatide is likely to be degraded by a baby’s digestive system before being absorbed, like happens with most large peptides. But “likely” isn’t the same as “proven safe,” which is why the current guidance is to avoid tirzepatide while breastfeeding until more research is done.
Other risks to consider
Even setting aside the question of transfer into breast milk, there are practical reasons tirzepatide isn’t recommended for breastfeeding women.
Milk supply
Tirzepatide works primarily by suppressing appetite. For a breastfeeding mother, this is a real concern because you should be consuming more calories, not less. Per the dietary guidelines for Americans, breastfeeding women should consume an extra 450–500 calories per day to sustain milk production. If you’re eating substantially less, as often happens while on tirzepatide, your milk supply could drop, potentially affecting your baby’s nutrition and growth.
Calorie restriction is one of the most well-documented causes of reduced milk supply. This alone is a good reason to hold off on tirzepatide while nursing.
Infant appetite regulation
GLP-1 hormones are naturally present in breast milk and play a role in infant appetite regulation. Since tirzepatide mimics both GLP-1 and GIP, there’s a concern—again, theoretical—that even small amounts passing into milk could interfere with how satisfied or hungry your baby feels. There’s no direct evidence this happens, but it’s a question researchers haven’t been able to rule out yet.
GLP-1 side effects
Common side effects of tirzepatide include nausea, diarrhea, vomiting, and constipation, all of which can affect fluid and nutrient intake. These risks are especially relevant during breastfeeding.
The unknown long-term picture
Much of what we know (or don’t know) about tirzepatide and breastfeeding is still theoretical. Given that the consequences of getting it wrong affect a vulnerable infant, most providers recommend avoiding GLP-1 medications altogether until breastfeeding is completely done.
What you can do instead
Not being able to take tirzepatide while nursing doesn’t mean you’re out of options. There are other meaningful ways to manage your weight during this period:
- Talk to your provider about safe alternatives. If you have an underlying medical condition, your provider can help you find a treatment plan that’s compatible with breastfeeding.
- Focus on nutritional quality. Prioritize protein, complex carbohydrates, and healthy fats rather than cutting calories. These food groups support both your recovery and your milk supply. They also tend to be more satiating so you’re less tempted to overindulge on processed foods full of empty calories.
- Strengthen your foundation. Sleep (as much as you can get), stress management, and movement all support your metabolic health and set the stage for effective weight loss once you’re ready to pursue it. These habits matter whether you're on tirzepatide or not.
The postpartum period can feel like it’s all about restrictions. But it can also be a time to reset. The habits worth building during the breastfeeding phase—balanced nutrition, consistent movement, good sleep—are the same ones that will help you later, and even make weight-loss support like tirzepatide even more effective when the timing is right.
When is it okay to start tirzepatide after breastfeeding?
The right timeline varies by person, but the general recommendation is to wait until milk production has fully stopped and your nutrition and hydration are stable. Your postpartum hormone levels, overall recovery, and whether you meet clinical criteria for tirzepatide will also factor in.
Consult with your provider on the best time to start tirzepatide after breastfeeding, especially if you’ve used it for diabetes management. Don’t stop or restart tirzepatide without medical guidance.
Frequently asked questions
Is tirzepatide safe during breastfeeding at any dose?
No. Current guidance doesn’t support tirzepatide use while breastfeeding at any dose, including compounded or microdose versions. The concern isn’t just about the drug appearing in breast milk; it also involves the appetite-suppressing effects and what that means for milk supply and infant nutrition.
Is compounded tirzepatide safer to use while nursing?
No. Compounded tirzepatide contains the same active ingredient as Zepbound and Mounjaro. The form of delivery doesn’t change the underlying safety concerns for breastfeeding women.
Can tirzepatide affect how much breast milk I produce?
Potentially. Tirzepatide reduces appetite, and nursing mothers need more calories, not less, to support milk production. Significant calorie restriction is a known contributor to lower milk supply.
What if I have type 2 diabetes and need tirzepatide to manage it?
This is a situation where the risks and benefits need to be weighed carefully with a medical provider. In some cases, continuing treatment may be the right call. Don’t make changes to diabetes medications without talking to your provider first.
Will I be able to start tirzepatide once I stop breastfeeding?
Most likely, once your provider confirms that you meet the clinical criteria and that your postpartum recovery is stable. Many women find tirzepatide to be a helpful tool for postpartum weight management once breastfeeding is concluded.
The bottom line on tirzepatide and breastfeeding
Tirzepatide can be a powerful weight-loss tool, but it is not appropriate for use while breastfeeding. More research in this area is needed before we know for sure whether tirzepatide is safe to use during breastfeeding.
If you have questions about postpartum weight management or when it might be appropriate to start tirzepatide, talk with a licensed provider who can evaluate your individual situation.
*Based on SURMOUNT-1 (NCT04184622), a phase 3, randomized, double-blind, placebo-controlled trial in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with ≥1 weight-related comorbidity, excluding T2D. Mean body weight reduction of 20.9% at 15 mg vs. 3.1% with placebo over 72 weeks.
This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting or changing any medication.
Compounded medications are prepared by licensed pharmacies to meet individual patient needs. While they are not reviewed or approved by the FDA for safety or effectiveness, they are made in accordance with strict regulatory guidelines. Prescription is only available after consultation with a licensed provider to determine if treatment is appropriate.
Tirzepatide (Zepbound®, Mounjaro®) carries a Boxed Warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additional serious risks include pancreatitis, gallbladder disease, hypoglycemia (when used with insulin), acute kidney injury, and severe hypersensitivity reactions. See full Prescribing Information.
